White Paper
Canadian Oncology Trends Report 2024
Trends in the Canadian oncology landscape impacting pharmaceutical launches
Nov 25, 2024
Profiles the state of research and development in oncology in Canada, including key mechanisms, and information analyzed by research sponsors. Trends in regulatory approval of novel active substances (NASs) over the last 10 years are reported along with market access timelines and Canadian oncology spending. A showcase of real-world data collected in non-small cell lung cancer (NSCLC) highlights treatment dynamics leveraging IQVIA syndicated and custom oncology offerings.

Related solutions

Contact Us